This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run ...
The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise. Eikon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback